Vor Bio Completes Phase 3 UPSTREAM MG Enrollment and Expands Telitacicept Into Ocular MG
BOSTON, Massachusetts — September 8, 2026 Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, Massachusetts — September 8, 2026 Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase...
